Literature DB >> 17556660

Knock-in mouse model of dilated cardiomyopathy caused by troponin mutation.

Cheng-Kun Du1, Sachio Morimoto, Kiyomasa Nishii, Reiko Minakami, Mika Ohta, Naoto Tadano, Qun-Wei Lu, Yuan-Yuan Wang, Dong-Yun Zhan, Misato Mochizuki, Satomi Kita, Yoshikazu Miwa, Fumi Takahashi-Yanaga, Takahiro Iwamoto, Iwao Ohtsuki, Toshiyuki Sasaguri.   

Abstract

We created knock-in mice in which a deletion of 3 base pairs coding for K210 in cardiac troponin (cTn)T found in familial dilated cardiomyopathy patients was introduced into endogenous genes. Membrane-permeabilized cardiac muscle fibers from mutant mice showed significantly lower Ca(2+) sensitivity in force generation than those from wild-type mice. Peak amplitude of Ca(2+) transient in cardiomyocytes was increased in mutant mice, and maximum isometric force produced by intact cardiac muscle fibers of mutant mice was not significantly different from that of wild-type mice, suggesting that Ca(2+) transient was augmented to compensate for decreased myofilament Ca(2+) sensitivity. Nevertheless, mutant mice developed marked cardiac enlargement, heart failure, and frequent sudden death recapitulating the phenotypes of dilated cardiomyopathy patients, indicating that global functional defect of the heart attributable to decreased myofilament Ca(2+) sensitivity could not be fully compensated by only increasing the intracellular Ca(2+) transient. We found that a positive inotropic agent, pimobendan, which directly increases myofilament Ca(2+) sensitivity, had profound effects of preventing cardiac enlargement, heart failure, and sudden death. These results verify the hypothesis that Ca(2+) desensitization of cardiac myofilament is the absolute cause of the pathogenesis of dilated cardiomyopathy associated with this mutation and strongly suggest that Ca(2+) sensitizers are beneficial for the treatment of dilated cardiomyopathy patients affected by sarcomeric regulatory protein mutations.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17556660     DOI: 10.1161/CIRCRESAHA.106.146670

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  81 in total

Review 1.  Where Does Inflammation Fit?

Authors:  Luigi M Biasucci; Giulio La Rosa; Daniela Pedicino; Alessia D'Aiello; Mattia Galli; Giovanna Liuzzo
Journal:  Curr Cardiol Rep       Date:  2017-09       Impact factor: 2.931

2.  Why is it important to analyze the cardiac sarcomere subproteome?

Authors:  R John Solaro; Chad M Warren; Sarah B Scruggs
Journal:  Expert Rev Proteomics       Date:  2010-06       Impact factor: 3.940

3.  Biological actions of green tea catechins on cardiac troponin C.

Authors:  Naoto Tadano; Cheng-Kun Du; Fumiaki Yumoto; Sachio Morimoto; Mika Ohta; Ming-Fang Xie; Koji Nagata; Dong-Yun Zhan; Qun-Wei Lu; Yoshikazu Miwa; Fumi Takahashi-Yanaga; Masaru Tanokura; Iwao Ohtsuki; Toshiyuki Sasaguri
Journal:  Br J Pharmacol       Date:  2010-11       Impact factor: 8.739

Review 4.  Phenotyping cardiomyopathy in adult zebrafish.

Authors:  Alexey V Dvornikov; Pieter P de Tombe; Xiaolei Xu
Journal:  Prog Biophys Mol Biol       Date:  2018-05-30       Impact factor: 3.667

5.  Disrupted mechanobiology links the molecular and cellular phenotypes in familial dilated cardiomyopathy.

Authors:  Sarah R Clippinger; Paige E Cloonan; Lina Greenberg; Melanie Ernst; W Tom Stump; Michael J Greenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2019-08-19       Impact factor: 11.205

6.  Cardiac myosin light chain phosphorylation and inotropic effects of a biased ligand, TRV120023, in a dilated cardiomyopathy model.

Authors:  Madhusudhan Tarigopula; Robert T Davis; Paul T Mungai; David M Ryba; David F Wieczorek; Conrad L Cowan; Jonathan D Violin; Beata M Wolska; R John Solaro
Journal:  Cardiovasc Res       Date:  2015-06-04       Impact factor: 10.787

7.  Functional Annotation of TNNT2 Variants of Uncertain Significance With Genome-Edited Cardiomyocytes.

Authors:  Wenjian Lv; Lyon Qiao; Nataliya Petrenko; Wenjun Li; Anjali T Owens; Chris McDermott-Roe; Kiran Musunuru
Journal:  Circulation       Date:  2018-12-11       Impact factor: 29.690

8.  Stage-dependent benefits and risks of pimobendan in mice with genetic dilated cardiomyopathy and progressive heart failure.

Authors:  Miki Nonaka; Sachio Morimoto; Takashi Murayama; Nagomi Kurebayashi; Lei Li; Yuan-Yuan Wang; Masaki Arioka; Tatsuya Yoshihara; Fumi Takahashi-Yanaga; Toshiyuki Sasaguri
Journal:  Br J Pharmacol       Date:  2015-03-17       Impact factor: 8.739

9.  A myosin activator improves actin assembly and sarcomere function of human-induced pluripotent stem cell-derived cardiomyocytes with a troponin T point mutation.

Authors:  K M Broughton; J Li; E Sarmah; C M Warren; Y-H Lin; M P Henze; V Sanchez-Freire; R J Solaro; B Russell
Journal:  Am J Physiol Heart Circ Physiol       Date:  2016-05-06       Impact factor: 4.733

10.  Challenging current paradigms related to cardiomyopathies. Are changes in the Ca2+ sensitivity of myofilaments containing cardiac troponin C mutations (G159D and L29Q) good predictors of the phenotypic outcomes?

Authors:  David Dweck; Nir Hus; James D Potter
Journal:  J Biol Chem       Date:  2008-09-26       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.